Related Experiment Video
Updated: Jun 26, 2026

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
Published on: February 6, 2019
Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a
Ruth Salo1, Stefan Ursu, Michael H Buonocore
1Department of Psychiatry and Behavioral Sciences, University of California, Davis, USA. resalo@ucdavis.edu
Methamphetamine (MA) abuse impairs behavioral control, leading to reduced reaction time adjustments after conflict. This suggests a compromised ability to adapt behavior, potentially fueling continued drug-seeking.
Area of Science:
- Neuroscience
- Addiction Research
- Cognitive Psychology
Background:
- Methamphetamine (MA) abuse causes neurotoxicity in frontostriatal regions, impacting cognitive functions.
- Behavioral control deficits are implicated in sustaining addictive behaviors associated with MA abuse.
Purpose of the Study:
- To investigate behavioral control patterns in MA dependence.
- To examine reaction time (RT) adjustments in response to conflict in MA abusers versus controls.
Main Methods:
- Fast-event-related functional magnetic resonance imaging (fMRI) was used.
- A Stroop task variant assessed error rates, RT conflict, and trial-to-trial adjustments in 12 MA-dependent subjects and 16 controls.
Main Results:
- MA abusers showed reduced RT adjustments and less right prefrontal cortex activation compared to controls.
- These differences were observed in conditions measuring behavioral regulation after conflict exposure.
- No group differences were found in accuracy or within-trial Stroop conflict effects.
Conclusions:
- MA abusers exhibit deficits in adapting behavior based on prior experiences, specifically in trial-to-trial RT adjustments.
- This failure to modify behavior after conflict may contribute to persistent drug-seeking behaviors in MA addiction.
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

